Aditxt Announces First AditxtEngage™ Event, Continuing Series of Investor Opportunities to Engage with Company
Aditxt Therapeutics, Inc. (Nasdaq: ADTX) announces the launch of AditxtEngage™, a new platform for investor engagement. The first event will take place on October 6, 2020, at 4:30 PM ET, featuring CEO Amro Albanna and moderated by Chris Lahiji of LD Micro. This initiative aims to inform stakeholders about the company’s growth and development, focusing on its biotechnologies for immune system health. Aditxt is known for its immune monitoring and reprogramming technologies, currently in the pre-clinical stage.
- Launch of AditxtEngage™ to foster investor engagement.
- First event scheduled with CEO Amro Albanna to provide insights into company growth.
- Immune reprogramming technology still in pre-clinical stage, indicating potential delays in commercial application.
First AditxtEngage™Event with Amro Albanna, CEO, to be held on Tuesday, October 6that 4:30pm ET
Mountain View, CA, Oct. 02, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aditx Therapeutics, Inc. (Aditxt) (the “Company”) (Nasdaq: ADTX), a life sciences company developing biotechnologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming, today announced the launch of AditxtEngage™, a continuing series of investor opportunities to engage with Aditxt.
The first AditxtEngage™event will be a live Q&A session held on Tuesday, October 6, 2020 from 4:30pm – 5:00pm ET. The kickoff speaker will be Amro Albanna, the Co-Founder and Chief Executive Officer of Aditxt. The event will be moderated by Chris Lahiji, Founder and President of LD Micro. The event can be accessed by following this link: https://zoom.us/webinar/register/WN_3E04akpNTzuqnpv9kYvaBA
AditxtEngage™is envisioned as a platform for engaging stakeholders with Aditxt and its mission. It is intended to provide additional color and context about the Company’s growth and development.
About Aditx Therapeutics
Aditxt is developing technologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming. The immune monitoring technology is designed to provide a personalized comprehensive profile of the immune system. The immune reprogramming technology is currently at the pre-clinical stage and is designed to retrain the immune system to induce tolerance with an objective of addressing rejection of transplanted organs, autoimmune diseases, and allergies. For more information, please visit: www.aditxt.com
Forward-Looking Statements
Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Forward looking statements include statements regarding the Company’s intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the Company’s ongoing and planned product development; the Company’s intellectual property position; the Company’s ability to develop commercial functions; expectations regarding product launch and revenue; the Company’s results of operations, cash needs, spending, financial condition, liquidity, prospects, growth and strategies; the industry in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as those risks more fully discussed in the section entitled “Risk Factors” in the Company’s prospectus, dated September 1, 2020, that was filed with the Securities and Exchange Commission under File No. 333-248491, as well as discussions of potential risks, uncertainties, and other important factors in the Company’s subsequent filings with the Securities and Exchange Commission. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations:
PCG Advisory
Jeff Ramson
Chief Executive Officer
IR@aditxt.com
646-762-4518
www.aditxt.com
FAQ
What is AditxtEngage™?
When is the first AditxtEngage™ event scheduled?
Who will speak at the first AditxtEngage™ event?
Where can I access the AditxtEngage™ event?
What technologies is Aditxt developing?
